Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib

Recruiting now · Not applicable

Conditions studied: Rheumatoid Arthritis

In brief

Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues. Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA). Nerve conduction studies (NCSs) are an essential tool in the evaluation of the peripheral nervous system. The sensory nerve action potential (SNAP) provides information on the sensory nerve axon and its pathway from the distal receptors in the skin to the dorsal root ganglia, while the compound muscle action potential (CMAP) is an assessment of the motor nerve fibers from their origins in the anterior horn cell to their termination along muscle fibers.

Key facts

Study ID

NCT06977035

Run by

Sohag University

People needed

60

Starts

2025-05-05

Expected to finish

2026-06-01

Last updated by the study team

2026-05-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients fulfill the 2010 ACR/EULAR classification criteria of RA
• Age above 18 years old.
• Patient cooperative and can answer questions

You may not qualify if…

• Other rheumatologic or collagen diseases.
• Age below 18 years and above 65 years.
• Uncooperative patients.
• Patients with other causes of peripheral neuropathy as Diabetes mellitus.

Where it is running

• Sohag University Hospital — Sohag, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.